

To: IA Medicaid P+T Committee

Aimovig (erenumab) is antibody that binds to the CGRP receptor FDA approved for prophylaxis of episodic and chronic migraine in adults. The other two agents in this class, galcanezumab and fremanezumab, bind to the ligand , CGRP. I am not aware of evidence that demonstrates this difference in mechanism is clinically significant. However, if only two agents in this class are approved as preferred by the committee, it could be argued that they should have different mechanisms of action.

Disclosure: I am a compensated speaker for Biogen

Thank you for your time,